The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Open accessAbstract
The β-chemokine receptor CCR5 is considered to be an attractive target for inhibition of macrophage-tropic (CCR5-using or R5) HIV-1 replication because individuals having a nonfunctional receptor (a homozygous 32-bp deletion in the CCR5 coding region) are apparently normal but resistant to infection with R5 HIV-1. In this study, we found that TAK-779, a nonpeptide compound with a small molecular weight (Mr 531.13), antagonized the binding of RANTES (regulated on activation, normal T cell expressed and secreted) to CCR5-expressing Chinese hamster ovary cells and blocked CCR5-mediated Ca 2+signaling at nanomolar concentrations. The inhibition of β-chemokine receptors by TAK-779 appeared to be specific to CCR5 because the compound antagonized CCR2b to a lesser extent but did not affect CCR1, CCR3, or CCR4. Consequently, TAK-779 displayed highly potent and selective inhibition of R5 HIV-1 replication without showing any cytotoxicity to the host cells. The compound inhibited the replication of R5 HIV-1 clinical isolates as well as a laboratory strain at a concentration of 1.6–3.7 nM in peripheral blood mononuclear cells, though it was totally inactive against T-cell line-tropic (CXCR4-using or X4) HIV-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Identification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., & Lusso, P. (1995) · Science · doi:10.1126/science.270.5243.1811 · Cited by 2,869
CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5270.1955 · Cited by 2,706
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81313-6 · Cited by 2,287
Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., & Doms, R. W. (1996) · Cell · doi:10.1016/s0092-8674(00)81314-8 · Cited by 1,833
Cited by
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Murphy, P. M., Baggiolini, M., Charo, I. F., Hébert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., & Power, C. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01439-x · Cited by 1,817
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
T-Cell Function and Migration — Two Sides of the Same Coin
von Andrian, U. H., & Mackay, C. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010053431407 · Cited by 1,437
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Mechanisms of Viral Membrane Fusion and Its Inhibition
Eckert, D. M., & Kim, P. S. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.777 · Cited by 1,282
The SCF ubiquitin ligase: insights into a molecular machine
Cardozo, T., & Pagano, M. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1471 · Cited by 1,114
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931
Chemokines: immunology's high impact factors
Mackay, C. R. (2001) · Nature Immunology · doi:10.1038/84298 · Cited by 845
Chemokine receptors: multifaceted therapeutic targets
Proudfoot, A. E. I. (2002) · Nature Reviews Immunology · doi:10.1038/nri722 · Cited by 752
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
RANTES: a versatile and controversial chemokine
Appay, V., & Rowland-Jones, S. L. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01812-3 · Cited by 650
Structure, Function, and Inhibition of Chemokines
Fernandez, E. J., & Lolis, E. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091901.115838 · Cited by 609
Kristiansen, K. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.05.002 · Cited by 609
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Cartier, L., Hartley, O., Dubois-Dauphin, M., & Krause, K.-H. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.021 · Cited by 509
Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells
Yi, L., Li, Z., Yuan, K., Qu, X., Chen, J., Wang, G., Zhang, H., Luo, H., Zhu, L., Jiang, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.20.11334-11339.2004 · Cited by 485
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
Cavrois, M., de Noronha, C., & Greene, W. C. (2002) · Nature Biotechnology · doi:10.1038/nbt745 · Cited by 475
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
The Inflammatory Chemokine CCL5 and Cancer Progression
Aldinucci, D., & Colombatti, A. (2014) · Mediators of Inflammation · doi:10.1155/2014/292376 · Cited by 438
Dragic, T., Trkola, A., Thompson, D. A. D., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090576697 · Cited by 426
Richman, D. D. (2001) · Nature · doi:10.1038/35073673 · Cited by 419
Mori, T., Doi, R., Koizumi, M., Toyoda, E., Ito, D., Kami, K., Masui, T., Fujimoto, K., Tamamura, H., Hiramatsu, K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.29.3.1 · Cited by 407
Inhibition of HIV Fusion with Multivalent Gold Nanoparticles
Bowman, M.-C., Ballard, T. E., Ackerson, C. J., Feldheim, D. L., Margolis, D. M., & Melander, C. (2008) · Journal of the American Chemical Society · doi:10.1021/ja710321g · Cited by 371
Horuk, R. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00014-4 · Cited by 344
Viral exploitation and subversion of the immune system through chemokine mimicry
Murphy, P. M. (2001) · Nature Immunology · doi:10.1038/84214 · Cited by 336
Ligand-selective receptor conformations revisited: the promise and the problem
Kenakin, T. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00167-6 · Cited by 321
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012519099 · Cited by 303
Chemokine receptor antagonists: overcoming developmental hurdles
Horuk, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2734 · Cited by 303
Watson, C., Jenkinson, S., Kazmierski, W., & Kenakin, T. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008565 · Cited by 302
Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221375398 · Cited by 299
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED
Alonzo III, F., Kozhaya, L., Rawlings, S. A., Reyes-Robles, T., DuMont, A. L., Myszka, D. G., Landau, N. R., Unutmaz, D., & Torres, V. J. (2013) · Nature · doi:10.1038/nature11724 · Cited by 291
Esté, J. A., & Telenti, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61052-6 · Cited by 287
Twenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress
Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281
The entry of entry inhibitors: A fusion of science and medicine
Moore, J. P., & Doms, R. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1932511100 · Cited by 278
Gorry, P. R., Bristol, G., Zack, J. A., Ritola, K., Swanstrom, R., Birch, C. J., Bell, J. E., Bannert, N., Crawford, K., Wang, H., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.21.10073-10089.2001 · Cited by 265
Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., & Debnath, A. K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4349-4359.2004 · Cited by 264
Weber, C., Weber, K. S. C., Klier, C., Gu, S., Wank, R., Horuk, R., & Nelson, P. J. (2001) · Blood · doi:10.1182/blood.v97.4.1144 · Cited by 262
Cell surface receptors, virus entry and tropism of primate lentiviruses
Clapham, P. R., & McKnight, Á. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-8-1809 · Cited by 256
Martin, N., Welsch, S., Jolly, C., Briggs, J. A. G., Vaux, D., & Sattentau, Q. J. (2010) · Journal of Virology · doi:10.1128/jvi.02651-09 · Cited by 199
Shiraishi, M., Aramaki, Y., Seto, M., Imoto, H., Nishikawa, Y., Kanzaki, N., Okamoto, M., Sawada, H., Nishimura, O., Baba, M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9906264 · Cited by 185
Self-citationHamdan, F. F., Audet, M., Garneau, P., Pelletier, J., & Bouvier, M. (2005) · SLAS Discovery · doi:10.1177/1087057105275344 · Cited by 183
“1 nM) that was previously reported from radioligand binding studies.(33) Taken together, the results presented here show that the developed double stable cell lines are suitable to measure and quantify receptor activation and inhibition in a pharmacologically relevant manner.”
ResultThe role of chemoattraction in cancer metastases
Moore, M. A. S. (2001) · BioEssays · doi:10.1002/bies.1095 · Cited by 138
Disruption of protein–protein interactions: Towards new targets for chemotherapy
Loregian, A., & Palù, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20356 · Cited by 108
Kenakin, T. P. (2017) · Pharmacology in Drug Discovery and Development · doi:10.1016/b978-0-12-803752-2.00001-6 · Cited by 1
Metadata
- Authors
- Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K., & Fujino, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-05-11
- Volume
- 96
- Issue
- 10
- Pages
- 5698-5703
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2140478082
- Cited by
- 751
- References
- 35
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.